Cardiol Therapeutics Registered (A) WKN: A2PA9E ISIN: CA14161Y2006 Forum: Aktien Thema: Hauptdiskussion

Hmm ging eher in die andere Richtung

Us vorbörse sind wir 45% im plus??? Gibts News 😃??

Top Leute an Board geholt, mal schauen wie es weitergeht :)

https://newsfilter.io/articles/breakthroughs-in-treating-killer-diseases-could-lengthen-life-57bf7c2bbd97099ad906ab3536301ab7

https://www.capegazette.com/article/rally-overturn-marijuana-legalization-veto-set-june-7/240844

Top 👍

https://youtu.be/dntOCeG0NA4

Einmal alles zu Cardiol, für die, die sich nicht nur für den Kurs interessieren.

https://ceo.ca/@newsfile/cardiol-therapeutics-appoints-teri-loxam-and-chris

https://www.cardiolrx.com/cardiol-therapeutics-announces-fda-investigational-new-drug-application-ind-authorization-for-multicenter-phase-ii-open-label-pilot-study-of-cardiolrx-for-recurrent-pericarditis/

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company’s multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indications

https://www.kapitalerhoehungen.de/kommentare/aktien-cardiol-therapeutics-tesla-bayer-ag

Ja echt übel

Was ein Besch.. Markt gerade.. übel.

Dr. Leslie Cooper, Jr., M.D. and Dr. Arvind Bhimaraj, M.D., MPH, Steering Committee members for Cardiol Therapeutics’ clinical trials, will participate in a Virtual Key Opinion Leader (KOL) Webcast hosted by Edward Nash, biotech analyst with Canaccord Genuity, LLC (US) on Thursday, April 21, 2022 at 1:00 pm EDT. The discussion will focus on the potential anti-fibrotic/anti-inflammatory mechanisms of cannabidiol (CBD) and the need for new therapeutic options for the treatment of acute myocarditis and other inflammatory cardiomyopathies that lead to myocardial fibrosis related heart failure. According to the NIH, there are approximately 73K cases of acute myocarditis in the U.S. annually, with no approved therapeutics.